303
Views
1
CrossRef citations to date
0
Altmetric
Obesity

Liraglutide for weight management: benefits and risks

, , , &
Pages 537-539 | Received 10 Nov 2016, Accepted 08 Dec 2016, Published online: 04 Jan 2017
 

Transparency

Declaration of funding

This commentary received no funding.

Declaration of financial/other relationships

B.T. has disclosed that he has received grant/research funding from Amgen, AstraZeneca, Merk Serono, Merk Sharp & Dohme, Novartis, Pfizer and Roche; he has also acted as a consultant/advisor to Amgen, AstraZeneca, Merck Serono and Sanofi, and been on speakers’ bureau for Amgen, Merck Serono and Sanofi. M.H., Y.Z., P.C., and Z.-M.L. have disclosed that they have no significant relationships with or financial interests in any commercial companies related to this study or article.

CMRO peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.